Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.54 |
| ▸ | GCGR | P47871 | 1/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477244 | 1.00 | MAPK14 (0.58) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL1387242 | 0.78 | MAPK14 (0.64) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL6749396 | 0.78 | MAPK14 (0.64) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL1387350 | 0.77 | MAPK14 (0.71) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL1387279 | 0.77 | MAPK14 (0.71) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL5504385 | 0.76 | NR4A2 (0.64) | MAPK14MAPK11MAPK13MAPK12PTGS2 | |
| SCHEMBL1387186 | 0.75 | MAPK14 (0.71) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL6752467 | 0.73 | MAPK14 (0.59) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL6752468 | 0.73 | MAPK14 (0.59) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL19864312 | 0.73 | MAPK14 (0.73) | MAPK14MAPK11MAPK13GCGRMAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7479501-B2 | Heteroaryl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2009-01-20 | — | — | US | disclosed |
| US-20050090501-A1 | Heteroaryl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
| EP-1140916-B1 | HETEROARYL-CYCLIC ACETALS | AVENTIS PHARMA LTD (GB) | 2002-11-13 | — | — | EP | disclosed |
| EP-1140916-A1 | HETEROARYL-CYCLIC ACETALS | Aventis Pharma Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035911-A1 | HETEROARYL-CYCLIC ACETALS | AVENTIS PHARMA LIMITED (GB) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090501-A1 | Heteroaryl-cyclic acetals | TNF, TNFRSF1A, CD40 | MAPK14 3415/4885MAPK11 2854/4885MAPK13 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.